SWTX.Springworks Therapeutics, INC

SCHEDULE: Goldman Sachs Discloses 0.0% Stake in Springworks Therapeutics

Sentiment:

Schedule 13G Amendment

📋All filings for Springworks Therapeutics, INC
🔒Login to Follow

The Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported a 0.0% beneficial ownership stake in Springworks Therapeutics, Inc. as of September 30, 2025.

Summary

  • The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Springworks Therapeutics, Inc.
  • As of September 30, 2025, The Goldman Sachs Group, Inc. beneficially owned 132 shares of Springworks Therapeutics, Inc. common stock, representing 0.0% of the class.
  • Goldman Sachs & Co. LLC also beneficially owned 132 shares of Springworks Therapeutics, Inc. common stock, representing 0.0% of the class.
  • For both reporting persons, shared voting power was 47 shares and shared dispositive power was 132 shares.
  • The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
  • The Goldman Sachs Group, Inc. is classified as a parent holding company, and Goldman Sachs & Co. LLC is classified as a broker or dealer and an investment adviser.

Sentiment

Score: 5

Explanation: The filing is a factual, regulatory disclosure of a very minor, passive ownership stake, carrying a neutral sentiment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of institutional ownership, indicating a very minor, passive investment by Goldman Sachs in Springworks Therapeutics. It does not provide insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

  • This filing represents a standard Schedule 13G disclosure, which is a common regulatory requirement for institutional investors holding less than 20% of a company's stock with a passive investment intent.
  • A 0.0% ownership stake is negligible and typically does not warrant comparison to significant institutional holdings in other companies or industry benchmarks, as it suggests a minimal or incidental position rather than a strategic investment.

Stakeholder Impact

  • Shareholders: The disclosure of a 0.0% passive stake by Goldman Sachs is unlikely to have any material impact on existing shareholders, as it does not signal a significant investment or change in control.

Key Dates

DateDescription
July 16, 2025Date of subscription for the Power of Attorney for both The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.
September 30, 2025Date of the event which required the filing of this statement (beneficial ownership snapshot).
October 8, 2025Date of signature for the Schedule 13G filing by Sam Prashanth, Attorney-in-fact for both reporting persons, and for the Joint Filing Agreement.
July 16, 2026Expiration date of the Power of Attorney, unless earlier revoked.

Keywords

Goldman Sachs, Springworks Therapeutics, Schedule 13G, beneficial ownership, institutional ownership, common stock, SEC filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.